Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe

The second half of 2021 has proved fruitful for the European research sites participating in the MP18 study. Our Leiden, The Netherlands, and Klecany, Czech Republic study sites have continued to enroll. Enrollment has begun for study sites in Moss, Norway, and Maastricht, The Netherlands.

This month, the MAPS Europe research team will open study sites at Charité Berlin and University Medical Center Hamburg-Eppendorf in Germany and  Kings College, London, at the South London and Maudsley NHS Foundation Trust (SLaM). 

The research team is working on the long-term follow-up (LTFU) study protocol for this study, which is intended to survey PTSD patients at least 6 months after they receive treatment. This protocol has been submitted to European regulators using the Voluntary Harmonisation Procedure (VHP). The team plans to release this protocol beginning in the Netherlands in early 2022.